Nasal Intubation Using a Parker Flex-tip Endotracheal Tube Compared to a Nasal RAE Tube

January 6, 2016 updated by: University of British Columbia

Nasal Intubation Using a Parker Flex-tip Endotracheal Tube With Posteriorly Facing Bevel Compared to a Nasal RAE Tube With Left Facing Bevel: A Randomized Study

The purpose of this study is to determine the degree of epistaxis following nasal intubation with either a nasal endotracheal (RAE) tube with bevel facing left or Parker Flex-Tip endotracheal tube with bevel facing posteriorly

The investigators hypothesize that a Parker Flex-Tip endotracheal tube when inserted with bevel facing posteriorly during nasal intubation may reduce the incidence of epistaxis intra and post-operatively. The investigators propose that using this style of endotracheal tube improves patient safety and comfort and facilitates ease and success of nasal intubation.

Study Overview

Detailed Description

  1. Purpose

    To investigate and describe the use of a Parker Flex-Tip endotracheal tube (ETT) with a posteriorly facing bevel for nasal intubation at Vancouver Coastal Health (VCH).

    The investigators wish to demonstrate that a Parker Flex-Tip ETT with a posterior facing bevel eases ETT insertion and reduces epistaxis compared to a standard nasal RAE endotracheal tube (RAE ETT) currently used at VCH. The investigators propose that using this method improves performance and reduces complications of nasal intubation.

  2. Hypothesis

    Our hypotheses are:

    • That a Parker Flex-Tip ETT with a posterior facing bevel may reduce the incidence of epistaxis
    • That a Parker Flex-Tip ETT with a posterior facing bevel may allow the anesthesiologist to successfully nasal intubate with more ease and fewer attempts.
    • That use of a Parker Flex-Tip ETT with a posterior facing bevel for nasal intubation is acceptable to anesthesiologists and patients
  3. Justification

    Justification for developing a new technique Endonasal intubation is a widely performed technique that allows administration of anesthetic during oral, dental and maxillofacial surgeries while allowing unimpeded access to the surgical site. Nasal intubation poses several challenges not encountered in oropharyngeal intubation. These include advancing the endotracheal tube through the highly vascularized delicate mucosa of the nasal passage, past protruding turbinates, and maneuvering through the sharply angulated nasopharyx to access the trachea (Hall).

    The most common complication associated with endonasal intubation is epistaxis due to nasal abrasion, most commonly in the anterior part of the nasal septum, which can range from mild blood tinged mucus to massive epistaxis (Tintinalli, O'Connell, Hall). The risk of epistaxis increases with the use of excessive force, large endotracheal tube, repeated unsuccessful attempts and abnormal pharyngeal anatomy (Hall ). Rarer complications of nasal intubation include traumatic avulsion of the turbinates, turbinate fracture, retro pharyngeal laceration, and bacteremia (Williams, Hall, Dinner).

    Common techniques used to reduce the risks associated with nasal intubation include the use of vasoconstrictors in the nasal canal, lubrication of the endotracheal tube, selection of a smaller tube, mechanical dilatation of the nasal cavity, deliberate maneuvering of the tube during intubation (Hall). Other more complicated techniques have included thermosoftening and using a curved tip suction catheter to help guide the endotracheal tube (Kim, Morimoto, Wart, Seo). Overall these precautions and interventions are complicated and often ineffective in reducing complications.

    The main justification for our study is the finding from a recent study by Sugiyama . (2014) that using a Parker Flex-Tip ETT with a bent flexible tip, and advancing with the aid of an anterior flexed stylette with bevel facing posteriorly reduced the incidence of epistaxis to 4% compared to 50%, with a standard ETT. In our practice the investigators have noticed epistaxis to be present more often than not with the present nasal RAE ETT. However, the investigators have not quantified this scientifically. This significant reduction of epistaxis with a Parker Flex-Tip ETT, offers a simple and effective way to enhance patient safety and improve user ease when nasal intubation is indicated, and will improve the quality of care in our practice.

    The Parker Flex-Tip in our proposed study is identical to the Parker Flex-Tip used in the study by Sugiyama. Based on the findings by Sugiyama , the tube should allow the ETT to curve towards the oropharynx as it approaches the curve of the nasopharynx and therefore reduce impact and damage to the pharyngeal mucosa. Positioning the bevel to face posteriorly will allow the tube to slide along the posterior wall and reduce the risk of turbinate abrasion as it is advanced. The soft and curved distal tip presumably curls inward when it is advanced past the curve and a larger surface area of the tip comes into contact with the mucous membrane, reducing the pressure on the pharyngeal mucosa. Overall, the investigators predict that these modifications will increase ease of insertion and reduce the number of attempts to successful intubation, which should improve user ease and decrease risk of pharyngeal bleeding.

    The investigators aim to conduct a clinical study in 20-30 patients randomized to either the standard nasal RAE tube currently employed in our hospital or the Parker Flex-Tip ETT to demonstrate the feasibility of our technique in reducing endonasal complications at VCH.

  4. Objectives - Primary and Secondary

    Our primary objective is to describe the incidence of epistaxis with the use of a Parker Flex-Tip endotracheal tube with bevel facing posteriorly during nasal intubation.

    Our secondary objectives are to describe the ease of use of a Parker Flex-Tip endotracheal tube with bevel facing posteriorly, as well as patient and operator satisfaction with the technique.

  5. Research Methods

    To fulfill our objectives the investigators aim to perform a study in a clinical phase.

    A. Clinical Phase:

    The investigators plan to perform a clinical randomized study assessing the ease of use and complication rate associated with of a Parker Flex-Tip ETT with a posterior facing bevel during nasal intubation compared to a standard nasal RAE ETT.

    Study Population:

    Between 20 and 30 ASA physical status I or II patients undergoing oral or maxillofacial surgery where a nasal intubation would be appropriate for surgical anesthesia.

    ASA Physical Status 1 - A normal healthy patient

    ASA Physical Status 2 - A patient with mild systemic disease

    ASA Physical Status 3 - A patient with severe systemic disease

    ASA Physical Status 4 - A patient with severe systemic disease that is a constant threat to life

    ASA Physical Status 5 - A moribund patient who is not expected to survive without the operation.

    Patients who have documented deformities that will hinder nasal intubation, patients with a history of trauma or surgery in the area of interest, a history of epistaxis or -coagulopathies will be excluded from the study. Opioid tolerant patients taking more than 30 mg oral morphine equivalent will also be excluded from the study.

    Randomization and Blinding:

    A staff member with no clinical involvement in the study will insert the group allocation into an opaque envelope and seal the envelope. At the induction of anesthesia the envelope will be opened and the anesthesiologist will prepare the assigned tracheal tube and insert it.

    Patients will be randomly allocated to one of two groups differentiated by the type of endotracheal tube used (either a standard nasal RAE endotracheal tube with the bevel facing left or Parker Flex-Tip ET tube with bevel facing posteriorly).

    Intra operative measurements will be obtained and recorded by the attending anesthetist.

    The assessment of the presence of a post operative nose bleed or nasal pain and discomfort will be measured and recorded by an investigator who is not the attending anesthetist for the case and who is blinded to the group allocation.

  6. Interventions

Patients who are scheduled for maxillofacial surgery where nasal intubation would be appropriate to deliver surgical anesthesia and who consent to participate will be studied. A single experienced operator with at least 5 years of clinical anesthetic experience will perform the clinical examination and intubation. Routine monitors will be applied and peripheral intravenous access will be established. Oxygen will be given via face mask. Anesthesia induction using intravenous fentanyl (2.5 mcg/kg), propofol (1-2 mg/kg) and rocuronium (0.5-1mg/kg) will be administered for muscle relaxation. The nostril that the patient finds easy to breathe through will be chosen for intubation. If nostril conditions are the same on both sides the right nostril will be preferred for intubation. The tracheal tube (internal diameter [ID] 7 mm for males or 6.0 mm for females) will be coated with lubricating gel and gently inserted into the patients' selected nostril. Those assigned to the Parker Flex-Tip endotracheal tube will have a curved stylette inserted in the tube before induction and the bevel will be inserted facing posteriorly. Those assigned to the standard nasal RAE endotracheal tube will have the bevel facing leftward. Both study groups will have the ETT warmed and lubricated prior to insertion.

If no resistance of the either endotracheal tube during advancement into the oropharynx is noted it will be defined as "smooth", and will be inserted into the trachea using direct laryngoscopy. In patients assigned to the Parker Flex-Tip endotracheal tube, the stylette will be withdrawn from the tube immediately after the tube passes through the nasopharynx and the tube will then be advanced into the trachea by direct laryngoscopy. If resistance is noted on insertion of either ETT it will be recorded as "impinged" and a mark will be made on the tube corresponding to the depth of insertion into the nostril to allow the distance between the tip of the tube and the mark to be measured. The assessment of the ease of insertion will only be made on the first attempt, with no manipulation applied against resistance.

The degree of epistaxis will be assessed by a blinded independent investigator immediately post intubation and up to 5 minutes post intubation, and along with ease of insertion, recorded. Quantity of epistaxis will be measured by swabbing the nasopharynx with a dry swab and measuring the difference in weight gain between the dry swab and blood soaked swab. Epistaxis will be evaluated based on the criteria established by Sugiyama . Four grades will be used:

  1. No epistaxis, no blood observed on either the surface of the tube or the posterior pharyngeal wall
  2. Mild epistaxis with blood apparent on the surface of the tube or posterior pharyngeal wall
  3. Moderate epistaxis with pooling of blood on the posterior pharyngeal wall
  4. Severe epistaxis with a large amount of blood in the pharynx impeding nasotracheal intubation and necessitating urgent orotracheal intubation

7. Study Outcome

The principal outcome is reduced epistaxis using the Parker Flex-Tip endotracheal tube when compared to the standard nasal RAE ETT with a left facing bevel.

Secondary outcomes will include:

  • Ease of tube insertion
  • Number of attempts to insert tube
  • Post-operative patient nasal pain (Visual Analogue Score anchored at 0= no pain & 10= maximum pain) and satisfaction scores
  • Operator assessment of procedure

    8. Statistical analysis

Sample size between 20 and 30. Using the results of Sugiyama (2014) study the investigators predict that the incidence of epistaxis will range between 50% and 4% in the RAE and Parker Flex-Tip group respectively. Fisher's exact test determined the sample size of at least 7 per group using α = 0.05 (two sided) and a power of 80%.

Descriptive statistics will be used to analyze success rate and to present the information gathered.

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • British Columbia
      • Vancouver, British Columbia, Canada, V6Z 1L8
        • University of British Columbia Department of Anesthesiology, Pharmacology and Therapeutics

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 63 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Male and female patients
  • Over 16 years of age. The investigators definitely do not want to recruit anyone under age 16 yr
  • Undergoing an oral or maxillofacial surgery where nasal intubation would be appropriate for surgical anesthesia
  • General anesthesia and nasal intubation discussed and planned in the preoperative assessment clinic
  • ASA physical status I or II patients undergoing oral or maxillofacial surgery where nasal intubation would be appropriate for surgical anesthesia.

ASA Physical Status 1 - A normal healthy patient ASA Physical Status 2 - A patient with mild systemic disease ASA Physical Status 3 - A patient with severe systemic disease ASA Physical Status 4 - A patient with severe systemic disease that is a constant threat to life ASA Physical Status 5 - A moribund patient who is not expected to survive without the operation

Exclusion Criteria:

  • Patients not clinically amenable to general anesthesia
  • Documented anatomical deformities in the region of interest which includes nasal passages, internal nasal turbinates and nasopharynx. These structures will henceforth be called"region of interest."
  • History of trauma in the region of interest
  • Previous surgery in the region of interest
  • Coagulation defects
  • Anticoagulant medication other than Low Dose Aspirin
  • History of recurrent epistaxis
  • Age less than 16 years.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Nasal intubation-Standard RAE ETT
This arm will receive nasal intubation with the standard RAE endotracheal tube with bevel facing left.
A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
Active Comparator: Nasal intubation-Parker Flex-Tip ETT
This arm will receive nasal intubation with the Parker Flex-tip ETT with bevel facing posteriorly.
A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reduced Epistaxis
Time Frame: Immediately post intubation

The degree of epistaxis will be assessed by a blinded independent investigator immediately post intubation, and along with ease of insertion, recorded. Quantity of epistaxis will be measured by swabbing the nasopharynx with a dry swab and measuring the difference in weight gain between the dry swab and blood soaked swab. Epistaxis will be evaluated based on the criteria established by Sugiyama et al. Four grades will be used:

  1. No epistaxis, no blood observed on either the surface of the tube or the posterior pharyngeal wall
  2. Mild epistaxis with blood apparent on the surface of the tube or posterior pharyngeal wall
  3. Moderate epistaxis with pooling of blood on the posterior pharyngeal wall
  4. Severe epistaxis with a large amount of blood in the pharynx impeding nasotracheal intubation and necessitating urgent orotracheal intubation
Immediately post intubation
Reduced Epistaxis
Time Frame: 5 minutes post intubation

The degree of epistaxis will be assessed by a blinded independent investigator 5 minutes post intubation, and along with ease of insertion, recorded. Quantity of epistaxis will be measured by swabbing the nasopharynx with a dry swab and measuring the difference in weight gain between the dry swab and blood soaked swab. Epistaxis will be evaluated based on the criteria established by Sugiyama et al. Four grades will be used:

  1. No epistaxis, no blood observed on either the surface of the tube or the posterior pharyngeal wall
  2. Mild epistaxis with blood apparent on the surface of the tube or posterior pharyngeal wall
  3. Moderate epistaxis with pooling of blood on the posterior pharyngeal wall
  4. Severe epistaxis with a large amount of blood in the pharynx impeding nasotracheal intubation and necessitating urgent orotracheal intubation
5 minutes post intubation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Ease of tube insertion
Time Frame: Immediately post intubation
if no resistance of the either endotracheal tube during advancement into the oropharynx is noted it will be defined as "smooth", and will be inserted into the trachea using direct laryngoscopy. In patients assigned to the Parker Flex-Tip endotracheal tube, the stylette will be withdrawn from the tube immediately after the tube passes through the nasopharynx and the tube will then be advanced into the trachea by direct laryngoscopy. If resistance is noted on insertion of either ETT it will be recorded as "impinged" and a mark will be made on the tube corresponding to the depth of insertion into the nostril to allow the distance between the tip of the tube and the mark to be measured. The assessment of the ease of insertion will only be made on the first attempt, with no manipulation applied against resistance.
Immediately post intubation
Number of attempts to insert tube
Time Frame: Immediately post intubation
Immediately post intubation
Post-operative patient nasal pain
Time Frame: Within 2 hours after extubation
Post-operative patient nasal pain (Visual Analogue Score anchored at 0= no pain & 10= maximum pain) and satisfaction scores. Patients will be monitored for epistaxis immediately post intubation and for up to two hours in the recovery or until patient is deemed suitable for transfer to the ward. No further monitoring required for study purposes thereafter.
Within 2 hours after extubation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Himat Vaghadia, MBBS, Vancouver Coastal Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Actual)

November 1, 2015

Study Completion (Actual)

November 1, 2015

Study Registration Dates

First Submitted

November 24, 2014

First Submitted That Met QC Criteria

December 9, 2014

First Posted (Estimate)

December 12, 2014

Study Record Updates

Last Update Posted (Estimate)

January 8, 2016

Last Update Submitted That Met QC Criteria

January 6, 2016

Last Verified

January 1, 2016

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Epistaxis

Clinical Trials on Nasal Intubation with nasal RAE endotracheal tube

3
Subscribe